Vaccine News and Research

Latest Vaccine News and Research

MHRA grants approval for second Pfizer/Biontech bivalent Covid-19 booster vaccine

Approval has today been granted by the Medicines and Healthcare products Regulatory Agency (MHRA) for a Pfizer/BioNTech 'bivalent' Covid vaccine that targets both the Original strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 sub-variants.

9 Nov 2022

Immunological responses against monkeypox virus concerning the 2022 outbreak

A new study aimed to analyze the kinetics of the pox-specific T-cell induction, the inflammatory profile, and the inflammatory profile in human cases of the current monkeypox outbreak.

9 Nov 2022

What is the role of adenoviruses in human health?

With advances in molecular biology informing recent developments in vaccinology, gene therapy, and other fields of medicine, human adenoviruses (HAdVs) have been of primary importance in medical research. A recent review looks at the promises of HAdVs, their potential dangers, and future challenges.

9 Nov 2022

The effect of vaccination-induced immunity on viral loads of SARS-CoV-2 Omicron variant

Researchers analyzed nationwide vaccination data and cycle threshold value data from four laboratories in Israel that conduct SARS-CoV-2 qRT-PCR tests to determine the effect of vaccination-induced immunity on the viral loads of the SARS-CoV-2 Omicron variant.

9 Nov 2022

Higher dose of pneumococcal vaccine improves antibody response in patients receiving rituximab for ANCA-associated vasculitis

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.

8 Nov 2022

Researchers identify 55 broadly reactive monoclonal antibodies to betacoronaviruses

In a recent study published in the journal Cell Host & Microbe, researchers pursued novel approaches that could help find monoclonal antibodies (mAbs) broadly targeting coronaviruses (CoVs), especially genera beta CoVs.

8 Nov 2022

Skipping methotrexate for one week after flu vaccine provides the same seroprotection as a two-week hold in RA patients

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that discontinuing methotrexate for one week after seasonal influenza vaccination provided the same seroprotection as a two-week discontinuation period in patients with rheumatoid arthritis.

8 Nov 2022

Study identifies novel inhibitors against SARS-CoV-2 main protease

In a recent study posted to the bioRxiv* server, researchers at the University of Arizona screened ~11 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (MPro)-inhibiting small compounds in the ZINC15 database using a structure-based in-silico screening method.

8 Nov 2022

Terasaki Innovation Summit to focus on improving technological, entrepreneurial translation of personalized medicines

The Terasaki Institute for Biomedical Innovation (TIBI) will be hosting the Terasaki Innovation Summit on March 8-10, 2023, at the UCLA Meyer & Renee Luskin Center in Los Angeles.

8 Nov 2022

Cancer drugs work better after vaccination with the Chinese Covid vaccine

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor.

8 Nov 2022

Hybrid immunity from vaccination and Omicron BA.1 or BA.5 breakthrough infections exhibits cross-reactive efficacy against BA.2.75

Researchers recently measured the neutralizing antibody titers against the wild-type strain of SARS-CoV-2 and the SARS-CoV-2 Omicron subvariants in healthcare workers fully vaccinated with three doses of the Comirnaty vaccine who experienced breakthrough Omicron infections.

8 Nov 2022

U.S. COVID-19 vaccine safety surveillance results for the over 65s

In a recent study posted to the medRxiv* server, researchers conducted near real-time safety monitoring in the United States (US) elderly population for 14 safety outcomes weekly following the coronavirus disease 2019 (COVID-19) vaccination

7 Nov 2022

Researchers compare the risk of myocarditis between Pfizer and Moderna COVID-19 vaccines

Incidence of myocarditis, pericarditis or myopericarditis is two- to threefold higher after a second dose of the Moderna Spikevax COVID-19 vaccine when compared to the Pfizer BioNTech COVID-19 vaccine; however, overall cases of heart inflammation with either vaccine are very rare, according to a study in the Journal of the American College of Cardiology.

7 Nov 2022

Modeling predicts a declining trend in monkeypox cases globally and on a country-specific scale

In a recent study posted to the medRxiv* server, researchers at Georgia State University, USA, generated short-term forecasts of new monkeypox cases using an ensemble and subepidemic model.

7 Nov 2022

Vaccine confidence declined significantly since the start of the pandemic, study suggests

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic.

7 Nov 2022

Multinational consensus to end COVID-19 pandemic

A new study recommended specific actions to end the coronavirus disease 2019 (COVID-19) pandemic.

7 Nov 2022

Evaluating dual direct-acting antivirals against persistent COVID-19

Researchers assessed the efficiency of dual direct-acting antivirals in treating persistent coronavirus disease 2019 (COVID-19).

7 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Beyond vaccines: emerging technologies capable of unlocking the promise of biologically targeted mRNA therapeutics

Researchers reviewed technology advancements that will unlock the promise of biologically targeted messenger ribonucleic acid (mRNA) therapeutics beyond vaccines.

7 Nov 2022

Does the time of day patients receive their COVID-19 vaccinations influence their clinical benefit?

Researchers investigated whether the time of day at which COVID-19 patients receive their SARS-CoV-2 vaccinations influences the vaccine effectiveness.

7 Nov 2022

Vaccine News and Research

Latest Vaccine News and Research

MHRA grants approval for second Pfizer/Biontech bivalent Covid-19 booster vaccine

Immunological responses against monkeypox virus concerning the 2022 outbreak

What is the role of adenoviruses in human health?

The effect of vaccination-induced immunity on viral loads of SARS-CoV-2 Omicron variant

Higher dose of pneumococcal vaccine improves antibody response in patients receiving rituximab for ANCA-associated vasculitis

Researchers identify 55 broadly reactive monoclonal antibodies to betacoronaviruses

Skipping methotrexate for one week after flu vaccine provides the same seroprotection as a two-week hold in RA patients

Study identifies novel inhibitors against SARS-CoV-2 main protease

Terasaki Innovation Summit to focus on improving technological, entrepreneurial translation of personalized medicines

Cancer drugs work better after vaccination with the Chinese Covid vaccine

Hybrid immunity from vaccination and Omicron BA.1 or BA.5 breakthrough infections exhibits cross-reactive efficacy against BA.2.75

U.S. COVID-19 vaccine safety surveillance results for the over 65s

Researchers compare the risk of myocarditis between Pfizer and Moderna COVID-19 vaccines

Modeling predicts a declining trend in monkeypox cases globally and on a country-specific scale

Vaccine confidence declined significantly since the start of the pandemic, study suggests

Multinational consensus to end COVID-19 pandemic

Evaluating dual direct-acting antivirals against persistent COVID-19

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

Beyond vaccines: emerging technologies capable of unlocking the promise of biologically targeted mRNA therapeutics

Does the time of day patients receive their COVID-19 vaccinations influence their clinical benefit?

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in